Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 5/20 | 0.33 |
| ▸ | NOS1 | P29475 | 5/20 | 0.33 |
| ▸ | NOS2 | P35228 | 5/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6584803 | 0.84 | AR (0.32) | ARL3MBTL1MAPT | |
| SCHEMBL5833268 | 0.82 | IDO1 (0.38) | NOS3NOS1NOS2HPGDALDH1A1 | |
| SCHEMBL6622616 | 0.79 | MAP3K5 (0.38) | ARMAPTHSD11B1 | |
| SCHEMBL5833356 | 0.75 | NOS3 (0.43) | NOS3NOS1NOS2L3MBTL1MAPT | |
| SCHEMBL2969912 | 0.73 | RAB9A (0.54) | HPGDPDE10AALDH1A1KDM4EMAPT | |
| SCHEMBL5833512 | 0.72 | NOS3 (0.45) | NOS3NOS1NOS2L3MBTL1 | |
| SCHEMBL18586993 | 0.71 | MAPT (0.45) | HPGDL3MBTL1ALDH1A1KDM4EMAPT | |
| SCHEMBL8090303 | 0.71 | MEN1 (0.47) | ALDH1A1MAPT | |
| SCHEMBL5833744 | 0.70 | HTR1B (0.43) | HTR1BHTR2BGPR65HPGDAR | |
| SCHEMBL11961418 | 0.69 | HTR1B (0.44) | HTR1BHTR2BGPR65HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7012078-B2 | 2-aminopyridines containing fused ring substituents | PFIZER INC. (US) | 2006-03-14 | — | — | US | disclosed |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| EP-1007520-B1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NOS INHIBITORS | PFIZER PROD INC (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20030149017-A1 | 2-Aminopyridines containing fused ring substituents | PFIZER INC. | 2003-08-07 | — | — | US | disclosed |
| EP-1155000-B1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS | PFIZER PROD INC (US) | 2003-07-16 | — | — | EP | disclosed |
| US-6372768-B2 | NERVOUS SYSTEM DISORDERS | PFIZER INC | 2002-04-16 | — | — | US | disclosed |
| US-20010049379-A1 | 2-aminopyridines containing fused ring substituents | LOWE JOHN ADAMS (US) | 2001-12-06 | — | — | US | disclosed |
| EP-1155000-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS | Pfizer Products Inc. (US) | 2001-11-21 | — | — | EP | disclosed |
| US-20010014689-A1 | 2-aminopyridines containing fused ring substituents | LOWE JOHN A (US) | 2001-08-16 | — | — | US | disclosed |
| US-6211208-B1 | INHIBITION OF NITRIC OXIDE SYNTHETASE, ANTIINFLAMMATORY AGENTS | PFIZER INC | 2001-04-03 | — | — | US | disclosed |
| WO-2000050400-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS | PFIZER PRODUCTS INC. (US) | 2000-08-31 | — | — | WO | disclosed |
| EP-1007520-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NOS INHIBITORS | Pfizer Products Inc. (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999010339-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149017-A1 | 2-Aminopyridines containing fused ring substituents | NOS2, NOS1, NOS3 | HTR1B 204/4885HTR2B 342/4885GPR65 1921/4885 |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | NOS1, NOS3, NPBWR1 | HTR1B 533/4885HTR2B 634/4885GPR65 732/4885 |
| US-20010014689-A1 | 2-aminopyridines containing fused ring substituents | CBR1, CBR3, NOS2 | HTR1B 539/4885HTR2B 833/4885GPR65 3485/4885 |
| US-20010049379-A1 | 2-aminopyridines containing fused ring substituents | NOS2, NOS1, NOS3 | HTR1B 204/4885HTR2B 342/4885GPR65 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.